A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease

Cancer Medicine

Volumn 3, Issue 5, 2014, Pages 1266-1274

  Severi, Gianluca ^a,b   Fitzgerald, Liesel M ^a   Muller, David C ^a,b   Pedersen, John ^a,c,d   Longano, Anthony ^d   Southey, Melissa C ^a,b   Hopper, John L ^a,b   English, Dallas R ^a,b   Giles, Graham G ^a,b   Mills, John ^c,d,e  

^a CANCER EPIDEMIOLOGY CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Tissupath Pty Ltd   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

AZGP1; Immunohistochemistry; MUC1; NKX3.1; P53; Prognostic markers; Prostate cancer specific death

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; MUCIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN AZGP1; PROTEIN NKX3.1; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; CANCER GRADING; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS;

ADULT; AGED; BIOMARKERS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84991506022     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.281     Document Type: Article

References (32)

1. Boyle, P., G. Severi, and G. G. Giles. 2003. The epidemiology of prostate cancer. Urol. Clin. North Am. 30:209-217.
2. Brenner, H., and V. Arndt. 2005. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J. Clin. Oncol. 23:441-447.
3. Gondos, A., F. Bray, T. Hakulinen, and H. Brenner. 2009. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann. Oncol. 20:564-573.
4. Bill-Axelson, A., L. Holmberg, H. Garmo, J. R. Rider, K. Taari, C. Busch, et al. 2014. Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med. 370:932-942.
5. Chun, F. K., A. Haese, S. A. Ahyai, J. Walz, N. Suardi, U. Capitanio, et al. 2008. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 113:701-709.
6. D'Amico, A. V., R. Whittington, S. B. Malkowicz, Y. H. Wu, M. Chen, M. Art, et al. 2000. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 55:572-577.
7. Kattan, M. W., J. Cuzick, G. Fisher, D. M. Berney, T. Oliver, C. S. Foster, et al. 2008. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 112:69-74.
8. Kattan, M. W., S. F. Shariat, B. Andrews, K. Zhu, E. Canto, K. Matsumoto, et al. 2003. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J. Clin. Oncol. 21:3573-3579.
9. O'Brien, B. A., R. J. Cohen, A. Ryan, S. Sengupta, and J. Mills. 2011. A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance. J. Urol. 186:1811-1817.
10. Tsourlakis, M. C., M. Schoop, C. Plass, H. Huland, M. Graefen, T. Steuber, et al. 2013. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. Hum. Pathol. 44:1789-1796.
11. Gannon, P. O., L. Lessard, L. M. Stevens, V. Forest, L. R. Begin, S. Minner, et al. 2013. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. Eur. J. Cancer. 49:2441-2448.
12. Grupp, K., M. Habermann, H. Sirma, R. Simon, S. Steurer, C. Hube-Magg, et al. 2014. High nuclear karyopherin alpha 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Mod. Pathol. 27:96-106.
13. Budaus, L., H. Huland, and M. Graefen. 2012. Controversies in the management of localized prostate cancer: radical prostatectomy still the standard of care. Crit. Rev. Oncol. Hematol. 84(Suppl. 1):e24-e29.
14. Wilt, T. J., R. MacDonald, I. Rutks, T. A. Shamliyan, B. C. Taylor, and R. L. Kane. 2008. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann. Intern. Med. 148:435-448.
15. Kudahetti, S. C., G. Fisher, L. Ambroisine, D. Prowse, M. W. Kattan, C. S. Foster, et al. 2010. Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. Pathology 42:519-523.
16. Cuzick, J., Z. H. Yang, G. Fisher, E. Tikishvili, S. Stone, J. S. Lanchbury, et al. 2013. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br. J. Cancer 108:2582-2589.
17. Che, M., M. DeSilvio, A. Pollack, D. J. Grignon, V. M. Venkatesan, G. E. Hanks, et al. 2007. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int. J. Radiat. Oncol. Biol. Phys. 69:1117-1123.
18. Kudahetti, S., G. Fisher, L. Ambroisine, C. Foster, V. Reuter, J. Eastham, et al. 2009. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int. 104:20-24.
19. Muller, D. C., G. G. Giles, J. T. Manning, J. L. Hopper, D. R. English, and G. Severi. 2011. Second to fourth digit ratio (2D:4D) and prostate cancer risk in the Melbourne Collaborative Cohort Study. Br. J. Cancer 105:438-440.
20. Severi, G., H. A. Morris, R. J. MacInnis, D. R. English, W. Tilley, J. L. Hopper, et al. 2006. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15:86-91.
21. Giles, G. G., G. Severi, M. R. McCredie, D. R. English, W. Johnson, J. L. Hopper, et al. 2001. Smoking and prostate cancer: findings from an Australian case-control study. Ann. Oncol. 12:761-765.
22. Severi, G., V. M. Hayes, E. J. Padilla, D. R. English, M. C. Southey, R. L. Sutherland, et al. 2007. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 16:610-612.
23. Eeles, R. A., Z. Kote-Jarai, A. A. Al Olama, G. G. Giles, M. Guy, G. Severi, et al. 2009. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 41:1116-1121.
24. Kalbfleisch, J. D., and J. F. Lawless. 1988. Likelihood analysis of multi-state models for disease incidence and mortality. Stat. Med. 7:149-160.
25. Lapointe, J., C. Li, J. P. Higgins, M. van de Rijn, E. Bair, K. Montgomery, et al. 2004. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA 101:811-816.
26. Cozzi, P. J., J. Wang, W. Delprado, A. C. Perkins, B. J. Allen, P. J. Russell, et al. 2005. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin. Exp. Metastasis 22:565-573.
27. Papadopoulos, I., E. Sivridis, A. Giatromanolaki, and M. I. Koukourakis. 2001. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin. Cancer Res. 7:1533-1538.
28. Henshall, S. M., L. G. Horvath, D. I. Quinn, S. A. Eggleton, J. J. Grygiel, P. D. Stricker, et al. 2006. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J. Natl. Cancer Inst. 98:1420-1424.
29. Bethel, C. R., D. Faith, X. Li, B. Guan, J. L. Hicks, F. Lan, et al. 2006. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res. 66:10683-10690.
30. Bethel, C. R., D. Faith, X. Li, B. Guan, J. L. Hicks, and F. Lan. 2008. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br. J. Cancer 99:1296-1301.
31. McMenamin, M. E., P. Soung, S. Perera, I. Kaplan, M. Loda, W. R. Sellers. 1999. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59:4291-4296.
32. Schmitz, M., G. Grignard, C. Margue, W. Dippel, C. Capesius, J. Mossong, et al. 2007. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int. J. Cancer 120:1284-1292.